{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T02:53:00Z","timestamp":1778640780281,"version":"3.51.4"},"reference-count":15,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,5,6]]},"published-print":{"date-parts":[[2016,6]]},"abstract":"\n Introduction<\/jats:title>\n The large number of treatment modalities for patients diagnosed with Meni\u00e8re's disease (MD) complicates the selection of the best available treatment as the comparative efficacy of these interventions is not clear. We aim to identify the treatment or treatments with the highest efficacy of current pharmacological and non-pharmacological treatments for MD.<\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n \n We will identify all available systematic reviews on the treatment of MD. An online database search will be conducted in association with the UK Cochrane Centre, particularly the Ear, Nose and Throat Group. We will screen the systematic reviews for eligible randomised controlled trials (RCTs) to execute a network meta-analysis. In addition, online databases will be checked for eligible RCTs on treatments that were published after the latest systematic search was conducted. The characteristics of each RCT will be summarised, including the general design, the participants, the interventions, the outcome measurements, the duration of therapy and adverse events. The risk of bias will be assessed by means of the Cochrane Collaboration's risk of bias tool. The included studies will be assessed for methodological and statistical heterogeneity; the latter will be quantified by means of the I\n 2<\/jats:sup>\n statistic. The primary outcome will be the efficacy of treatment in terms of control of vertigo attacks. Secondary outcome measures will be the loss or improvement of hearing, severity of vertigo attacks and tinnitus, perception of aural fullness, quality of life, and the incidence of adverse events and complications.\n <\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n Formal ethical approval is not required as primary data will not be collected. The review will be disseminated in peer-reviewed publications and conference presentations.<\/jats:p>\n <\/jats:sec>\n \n PROSPERO registration number<\/jats:title>\n CRD42015024243.<\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010269","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T22:34:25Z","timestamp":1465598065000},"page":"e010269","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Interventions for Meni\u00e8re's disease: protocol for an umbrella systematic review and a network meta-analysis"],"prefix":"10.1136","volume":"6","author":[{"given":"Babette F","family":"van Esch","sequence":"first","affiliation":[{"name":"Apeldoorn Dizziness Centre, Gelre Hospital, Apeldoorn, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hester J","family":"van der Zaag-Loonen","sequence":"additional","affiliation":[{"name":"Apeldoorn Dizziness Centre, Gelre Hospital, Apeldoorn, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tjasse D","family":"Bruintjes","sequence":"additional","affiliation":[{"name":"Apeldoorn Dizziness Centre, Gelre Hospital, Apeldoorn, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Paul G","family":"van Benthem","sequence":"additional","affiliation":[{"name":"Leiden University Medical Centre, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,6,9]]},"reference":[{"key":"2025120520173920000_6.6.e010269.1","first-page":"597","article-title":"Memoire sur les lesions de l'orellei interne dinnant lieu \u00e0 des sympt\u00f4mes de congestion cerebrale apolectiforme","volume":"16","author":"Meni\u00e8re","year":"1861","journal-title":"Gazette Med Paris"},{"key":"2025120520173920000_6.6.e010269.2","doi-asserted-by":"publisher","DOI":"10.1097\/00019052-200402000-00004"},{"key":"2025120520173920000_6.6.e010269.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0038-8"},{"key":"2025120520173920000_6.6.e010269.4","doi-asserted-by":"publisher","DOI":"10.1097\/01.psy.0000232269.17906.92"},{"key":"2025120520173920000_6.6.e010269.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61161-7"},{"key":"2025120520173920000_6.6.e010269.6","doi-asserted-by":"crossref","unstructured":"James AL , Burton MJ . Betahistine for M\u00e9ni\u00e8re's disease or syndrome. Cochrane Databsase Syst Rev 2001;(1):CD001873.","DOI":"10.1002\/14651858.CD001873"},{"key":"2025120520173920000_6.6.e010269.7","doi-asserted-by":"crossref","unstructured":"Thirlwall AS , Kundu S . Diuretics for M\u00e9ni\u00e8re's disease or syndrome. Cochrane Database Syst Rev 2006;(3):CD003599. doi:10.1002\/14651858.CD003599.pub2","DOI":"10.1002\/14651858.CD003599.pub2"},{"key":"2025120520173920000_6.6.e010269.8","doi-asserted-by":"crossref","unstructured":"Phillips JS , Westerberg B . Intratympanic steroids for M\u00e9ni\u00e8re's disease or syndrome. Cochrane Database Syst Rev 2011;(7):CD008514. doi:10.1002\/14651858.CD008514.pub2","DOI":"10.1002\/14651858.CD008514.pub2"},{"key":"2025120520173920000_6.6.e010269.9","doi-asserted-by":"crossref","unstructured":"Pullens B , van Benthem PP . Intratympanic gentamicin for M\u00e9ni\u00e8re's disease or syndrome. Cochrane Database Syst Rev 2011;(3):CD008234. doi:10.1002\/14651858.CD008234.pub2","DOI":"10.1002\/14651858.CD008234.pub2"},{"key":"2025120520173920000_6.6.e010269.10","first-page":"CD005395","article-title":"Surgery for M\u00e9ni\u00e8re's disease","volume":"2","author":"Pullens","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120520173920000_6.6.e010269.11","first-page":"CD00008419","article-title":"Positive pressure therapy for M\u00e9ni\u00e8re's disease or syndrome","volume":"3","author":"van Sonsbeek","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2025120520173920000_6.6.e010269.12","doi-asserted-by":"crossref","first-page":"g7647","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2014","journal-title":"BMJ"},{"key":"2025120520173920000_6.6.e010269.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0194-5998(95)70102-8"},{"key":"2025120520173920000_6.6.e010269.14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/VES-150549","article-title":"Diagnostic criteria for Meni\u00e8re's disease","volume":"25","author":"Lopez-Escamez","year":"2015","journal-title":"J Vestib Res"},{"key":"2025120520173920000_6.6.e010269.15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T04:17:48Z","timestamp":1764994668000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,6,9]]},"published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1136\/bmjopen-2015-010269"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010269","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}